Voranigo is a new targeted drug approved by the U.S. FDA in 2024, indicated for the treatment of gliomas associated with specific gene mutations. As an IDH1/IDH2 inhibitor, it exerts therapeutic effects by precisely regulating tumor metabolism.

Indications for Voranigo

Primary Indications

Voranigo is indicated for adult and pediatric patients 12 years of age and older. It is used to treat grade 2 astrocytoma or oligodendroglioma after surgical resection (including biopsy, partial resection, or complete resection), with the requirement that the presence of IDH1 or IDH2 susceptible mutations must be confirmed by testing.

Key Instructions

Patient Selection: Before medication administration, the IDH1/IDH2 mutation status must be confirmed through tumor tissue testing. Currently, there are no FDA-approved companion diagnostic reagents, so laboratory-developed tests must be relied on.

Treatment Phase: It is limited to adjuvant therapy after surgery and cannot replace traditional treatments such as surgery or radiotherapy.

Age Restriction: The safety and efficacy in children under 12 years of age have not been established, and careful assessment is required.

Dosage Forms and Characteristics of Voranigo

Drug Specifications

10mg Tablets: White to off-white round tablets, imprinted with black "10" on one side and blank on the other. Each bottle contains 30 tablets, equipped with a moisture-proof container and a child-resistant cap.

40mg Tablets: White to off-white oval tablets, imprinted with black "40" on one side and blank on the other. The packaging is the same as that of the 10mg specification.

Storage Methods for Voranigo

Temperature Control

It is recommended to store at room temperature between 20°C and 25°C (68°F and 77°F), with short-term fluctuations between 15°C and 30°C (59°F and 86°F) allowed.

Avoid freezing or exposure to high temperatures (e.g., inside a car, bathroom).

Moisture-Proof Measures

The original packaging bottle contains a desiccant container. Do not remove or ingest the desiccant during use.

After opening the bottle, close the cap tightly immediately to prevent moisture intrusion.

Safe Storage

Use the child-resistant cap and store it in a place out of the reach of children and pets.

Avoid direct sunlight or humid environments (e.g., refrigerators).

Special Note: If the tablets change color, become damaged, or the desiccant fails (e.g., container swelling), the product should be discarded and a pharmacist contacted.